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Abstract A variety of luminal antigens, including a wide
range of drugs, have been associated with the still little-
known pathophysiology of microscopic colitis (MC), with
variable evidence suggesting causality. This article aims to
review the aspects related to drugs as potential triggers of
MC; to discuss the most commonly identified associations
between drugs and MC; and to analyze the limitations of
the studies currently available. A literature search was
performed in PubMed combining the search terms ‘drug
exposure’, ‘drug consumption’, and ‘risk factors’ with
‘microscopic colitis’, ‘lymphocytic colitis’, and ‘collage-
nous colitis’, with no language restrictions. Reference lists
of retrieved documents were also reviewed. A handful of
case–control studies have demonstrated significant associ-
ations between some commonly used drugs and a higher
risk of developing MC. No universally accepted criteria for
establishing cause–effect relationships in adverse reactions
to drugs are available, but several methods that can be
applied to MC, can provide degrees of the likelihood of an
association. A high probability imputation in the develop-
ment of MC as a drug adverse effect has only been
demonstrated for individual cases by applying chronolog-
ical (challenge, de-challenge, and relapse with re-chal-
lenge) and semiological criteria. Several case–control
studies have shown significant associations between
exposure to drugs and MC, but the variability in their
design, the reference populations used, and the definitions
for drug exposure considered require specific analyses. It
can be concluded that drug exposure and MC as a likely
cause–effect relationship has only been described for a
handful of drugs and in individual cases.
Key Points
Several studies, mainly retrospective case-control
studies, have associated microscopic colitis with
exposure to some commonly used drugs.
Chronic diarrhea constitutes the main clinical
presentation of microscopic colitis, and may appear
as a common side effect of multiple drugs.
A certain cause–effect relationship between drug
exposure and microscopic colitis has only been
described in a handful of drugs and in individual
cases, with additional evidence suggesting that drugs
are not involved in the majority of microscopic
colitis cases.
1 Introduction
The term microscopic colitis (MC) brings together a family
of chronic inflammatory bowel diseases, including the
principal entities of lymphocytic colitis (LC) and collage-
nous colitis (CC). Both are characterized by chronic or
intermittent watery diarrhea, a normal or near-normal
aspect of the colon in colonoscopy, and specific
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abnormalities in biopsies obtained from the colonic mucosa
that distinguish an entity separate from any other [1–3]:
While both LC and CC share chronic inflammation in the
lamina propria, an infiltration by more than 20 intraep-
ithelial lymphocytes per 100 epithelial cells is required to
warrant a diagnosis of LC. The key histological feature of
CC is a broad subepithelial fibrous band [10 lm in
thickness, immediately underneath the surface epithelium
[2].
Since the characterization of the disease during the
1970s and 1980s [4–8], the incidence and prevalence of
MC have developed from being a rare disorder to becom-
ing a common cause for watery chronic diarrhea in our
environment. A recent meta-analysis of epidemiological
studies has shown an overall incidence rate for CC of 4.14
[95% confidence interval (CI) 2.89–5.40] new cases per
100,000 inhabitants per year, and for LC of 4.85 (95% CI
3.45–6.25) [9]. Up to 10% of patients currently investi-
gated because of watery non-bloody chronic diarrhea are
diagnosed as MC, reaching 20% in subjects aged over 70
years, and being especially prevalent in older women and
smokers [2]. A significant diagnostic overlap between
diarrhea-dominant functional bowel disorders and MC has
been recognized, with up to 10% of patients with irrita-
ble bowel syndrome truly presenting with MC [10].
Despite its relative frequency, the etiology of MC
remains unknown [11]. The most common theories propose
that MC results from the activation of the immune system
in the colonic mucosa in response to exposure to different
luminal antigenic factors [12], such as toxins, infections,
bile acids, or drugs. In fact, the resolution of histopatho-
logical changes after bypassing mucosal intestinal transit
suggests that luminal antigens are directly involved in the
pathogenesis of MC [13–15]. It has recently been demon-
strated that human leukocyte antigen-related immune
mechanisms contribute to the dysregulated inflammation
characterizing the disease [16, 17].
The potential infectious etiology for MC is based on
several clinical observations, including the development of
MC after an intestinal infection by Clostridium difficile
[18, 19] or the higher frequency of antibodies against
Yersinia enterocolitica and other infectious agents in the
sera of CC patients compared with control subjects [20].
However, a specific pathogen has not been identified in
patients with MC so far.
The potential effect of bile acids in the development of
MC has been based on experimental models of the disease
in animals [12, 22], the frequent appearance of diarrhea
with bile acid malabsorption after an ileal resection [23],
and the demonstration that there is malabsorption in a
significant proportion of patients with LC and CC [24, 25].
Despite these factors, there is no conclusive scientific
evidence on the etiological role of bile acids in MC, and
treatment with bile acid sequestrants do not result in
remission of histological lesions in these patients [26].
The concept that some drugs could cause or worsen MC
was initially proposed in the early 1990s [27, 28]. As a
consequence, drug consumption has been repeatedly con-
sidered as an environmental risk factor involved in trig-
gering or precipitating MC. A range of evidence, from
individual case reports to clinical cases and even obser-
vational epidemiological studies, have implicated several
frequently used drugs as potential causes of LC and CC,
after documenting significant associations between the two
phenomena. The recent American Gastroenterological
Institute Guidelines for the management of MC in fact
considers several drugs, including non-steroidal anti-in-
flammatory drugs (NSAIDs), aspirin, proton pump inhibi-
tors (PPIs), selective serotonin reuptake inhibitors (SSRIs),
clozapine, and acarbose as precipitating causes for MC
[29]. However, the degree of cause–effect plausibility on
which these observations are supported is widely variable
[30].
Moreover, it is essential to consider that diarrhea is a
common side effect of many medications, accounting for
up to 7% of overall drug adverse events, triggered through
different pathophysiological mechanisms, which are often
multi-factorial [31–33]. More than 700 drugs have been
recognized as a potential cause of diarrhea. These drugs
also commonly affect elderly patients [34] because of their
increased susceptibility to the toxic effects; metabolism
inherent in the aging process, and the polypharmacy to
which this population is subjected. This group of patients is
the most likely to suffer from MC according to the majority
of available epidemiological studies.
This review aims to analyze in depth the aspects related
to the use of drugs as a potential cause of MC, presenting
the most commonly identified associations with MC, and
discussing the limitations of the available studies focused
on this association. A search was conducted in PubMed on
the association of MC and drug consumption, by combin-
ing the terms ‘drug exposure’ OR ‘drug consumption’ OR
‘risk factors’ with ‘microscopic colitis’ OR ‘lymphocytic
colitis’ OR ‘collagenous colitis’. All papers were included
from the origin of records up to May 2016, with no
restriction on language or publication time. Reference lists
of retrieved documents were also reviewed to find addi-
tional information.
2 Causal Relationships Between Drug Exposure
and Adverse Effects: Criteria and Limitations
Cause–effect relationships between exposure to a specific
drug and the development of an adverse effect have been
analyzed using a range of methods, but universally
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accepted criteria are currently lacking [35]. These methods
can be grouped into three different categories: (1) expert
judgment based on global insights; (2) algorithms, and (3)
Bayesian or probabilistic methods.
The World Health Organization program for interna-
tional drug monitoring has proposed a system based on the
expert judgment [36, 37] method, in which different cate-
gories of causality are established based on (1) the tem-
poral sequence and timing between cause and effect; (2)
prior information on the drug; (3) the dose–response rela-
tionship; (4) the pattern of response to the drug; (5) the re-
challenge (looking for a relapse event in administering the
drug again); (6) the exclusion of other alternative etiologic
candidates; and (7) exposure to concomitant drugs. With
this system, adverse events are thus classified as ‘certain’,
‘probable’, ‘possible’, ‘unlikely’, and ‘not assessable’
(Table 1).
Algorithms use structured and standardized methods for
evaluating possible adverse effects of drugs, using a sys-
tematic approach. While providing a higher level of con-
sistency and reproducibility than previous methods, some
points still require clinical judgment to reach a conclusion.
Among the algorithms, the so-called ‘French method’
(owing to having been employed by regulatory agencies in
this country) [38] has been used specifically to assess the
imputability of drugs in the origin of MC [39] (Table 2).
The method employs three chronological criteria (drug
challenge, de-challenge, and re-challenge) and four semi-
ological criteria (suggestive clinical signs; favoring factor;
alternative non-drug-related explanation, and specific lab-
oratory tests). The overall score from these seven criteria
allows classification as ‘likely’, ‘possible’, and ‘dubious’.
Agreement between the two methods for assessing the
imputability of drugs on side effects, if any, has been
demonstrated to be very low in a comparative study, with
agreement degrees given between 61 and 17% for the
different categories [78]. Finally, probabilistic methods to
assess the causality of adverse reactions to drugs use the
findings of a specific case to transform the prior
probabilities in posterior probabilities by calculating like-
lihood ratios for each of the relevant elements of the case
[79]. The main advantage of these methods is the possi-
bility of simultaneously evaluating multiple potential cau-
ses, along with the possibility of automating the process.
3 Association Between Drug Exposure
and Development of MC
Large prospective longitudinal studies analyzing the causal
relationship between drug exposure and the risk of devel-
oping MC are lacking [3]. Currently available evidence on
the ability of drugs to trigger MC comes from several
sources. Knowledge of these is essential to accurately
assess the risks of bias inherent in the design of the studies
addressing this topic.
3.1 Case Reports
These descriptions include a limited number of patients,
since the early 1990s, in whom several drugs have been
repeatedly involved in the risk of developing MC [27–51].
Although the list of potential drugs is long, a certain causal
likelihood (based on the temporal relationship between
exposure and symptoms; resolution of clinical and patho-
logical findings after drug withdrawal; and relapse after re-
challenge) has only been demonstrated for a small number
of drugs, including acarbose [40], NSAIDs [51], ranitidine
[72], omeprazole [71], lansoprazole [67], ticlopinin [75],
and venotonic drug Cyclo 3 Fort (Pierre Fabre Medica-
ment, Paris, France) [80]. However, in some cases, the re-
challenge assessment exclusively involved clinical relapse,
without obtaining new colonic biopsies [51, 75].
3.2 Case–Control Studies
Both prospective and retrospective case–control studies
have demonstrated an association between a higher chance
Table 1 Causality categories in adverse reactions to drugs (adapted from WHO) [35, 36]
Probability Criteria
Certain Compatible timing of the event relative to drug exposure and improvement of the symptoms after stopping the medication and
recurrence of the symptoms (and other morphological alterations, if required) on repeat exposure or other definite proof
Probable Compatible timing of the event relative to drug exposure and improvement of the symptoms after stopping the medication and
the event is not attributable to the patient’s clinical status
Possible Compatible timing of the event relative to drug exposure but the event could also be attributable to the patient’s clinical status
Unlikely All reactions not fulfilling the aforementioned criteria
Unclassifiable Insufficient data
WHO World Health Organization
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of MC (or any of its types) and exposition to a defined drug
product, but they do not allow the establishment of cause–
effect relationships (Table 3). However, the main benefit of
these studies is that they proposed potential pharmacologic
risk factors to be further investigated through causality
tests.
The exposition to PPIs, especially omeprazole and lan-
soprazole, has been related to an overall increased risk of
developing MC [81, 86, 87]. In fact, several observational
studies have involved PPIs as the drugs with the main risk
of prompting the development of MC [81, 83, 86, 87]. The
association of MC with other active principles within the
PPI family (including pantoprazole, rabeprazole, and
esomeprazole) was specifically dispelled by a recent case–
control study [87].
The association between exposure to PPIs and MC has
been, in general, more intense and more frequently repor-
ted for CC than for LC [52, 82, 83], and for the most
symptomatic forms of MC [88]. Continuous exposure to
PPIs over a period of 4–12 months was associated with an
increased risk of MC; its prolonged and continuous use for
more than 1 year reduced this risk. A cause–effect rela-
tionship between the dose of PPIs and the risk of devel-
oping MC has not been demonstrated [87].
Histamine-2 receptor antagonist drugs have been
involved in the increased risk of presentingMC in individual
case reports [72] and also in case–control studies [87]. This
leads us to consider that, beyond themolecule’s own effect in
promptingMC, its pharmacological effect by inhibiting acid
secretion and raising gastric pH might also be related to the
development of MC, either by increasing the permeability
and altering the function of the intestinal barrier [89] or by
modifying the intestinal microbiota composition [90].
Exposure to NSAIDs (in general), including aspirin at
low doses (\300 mg daily), has been linked with an
increased risk of MC in each of its two CL and CC
variants, in six studies [34, 52, 82, 83, 86, 87]. Experi-
mental studies support a pathogenic role for NSAIDs and
aspirin on the intestinal barrier, over both the mucous
layer and enterocytes, leading to dysfunction and
increased intestinal permeability followed by enhanced
exposure to luminal triggers and acute inflammation [91].
This association, however, has not been universally
reproduced in other similarly designed research [92].
Furthermore, concomitantly using NSAIDs with PPIs
(two drugs that are frequently prescribed in combination)
compared with each of these drugs separately has been
shown to increase the risk of MC according to a recent
case–control study [87].
A link between the exposure to SSRIs, especially ser-
traline, and an increased risk of MC has been documented
in several studies [34, 52, 83], in patients with both CC and
CL. Serotonin accelerates the intestinal motility and pro-
motes water and electrolyte secretion, with a secondary
compensatory increased expression in peptide YY, as
observed in LC patients [21]. However, other studies have
not shown this association [87].
Studies have associated, though not universally [85],
MC with exposure to statins [34, 83, 87], b-blockers
[34, 52, 86], and biphosphonates [34]. Differences in the
exposure to these drugs in MC patients and patients with
chronic diarrhea were not demonstrated in another study
[84], suggesting that these drugs could behave like diarrhea
inducers instead of true triggers of MC. Less frequently,
significant associations between MC and the use of
angiotensin-converting enzyme inhibitors [86], angiotensin
Table 2 Assessment of levels of probability with which different drugs can trigger microscopic colitis: review of the literature (amended from
Beaugerie and Pardi) [40]
High likelihood to cause microscopic
colitis
Intermediate likelihood to cause microscopic
colitis
Low likelihood to cause microscopic colitis
Acarbose [40] Carbamazepine [41–43] Cimetidine [45]
Aspirin and NSAIDs [46–51] Celecoxib [52] Gold salts [53]
Clozapine [54] Duloxetine [55] Piascledine [56]
Entocapone [57] Fluvastatin [52] Pembrolizumab [58]
Flavonoidsa [39, 52, 59–62] Flutamide [53, 63] Topiramate [92]
Lansoprazole [64–68] Oxetorone [69, 70] Angiotensin-converting enzyme inhibitors
[86]
Omeprazole/esomeprazole [71] Modopar b [73] Bisphosphonates [34]
Ranitidine [72] Paroxetine [41] Angiotensin II receptor blockers [52]
Sertraline [39, 41, 52] Simvastatin [83] b-Blockers [34, 52, 86]
Ticlopidine [53, 63, 74–77] Stalevo b [60]
a Venotonic drugs containing flavonoids (diosmine, rutine, and hesperidine)
b Modopar is an antiparkinson drug containing levodopa and benseracide; Stalevo is an antiparkinson drug containing carbidopa, levodopa,
and entocapone
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II receptor blockers [52] and, recently, topiramate [92]
have been also reported.
The recent introduction of a new drug (within the last 3
months) has been identified as a significant risk factor
associated with MC [84, 87], especially in the case of PPIs,
NSAIDs, SSRIs, or anti-Parkinson drugs, compared with
never having taken the drug, or having taken it in the past.
In this regard, the induction of diarrhea or its deterioration
after exposure to drugs may also encourage a colonoscopy
examination to facilitate the diagnosis of an underlying
MC, which would not necessarily be directly caused by the
drug. In contrast, the exposure time to drugs specifically
associated with MC was identified in another study [52] as
being generally long (15–60 months).
3.3 Drug Prescription Records
The two case–control studies available based on this
methodology yielded opposing results. While a large Danish
national study including 5751 patients diagnosed with CC or
CL found a significant association with PPI, statin, NSAID,
and SSRI prescriptions [83], research carried out in Penn-
sylvania (USA) found no association between MC and the
prescribing of several drugs commonly related with MC
[93]. However, the degree of concordance between the
consumption of drugs declared by patients and the data
recorded on the database was generally low.
4 Effect of the Dose of Drugs on the Risk of MC
Despite some case–control studies having shown that low
doses of aspirin were associated with an increased risk of
MC in its two types [52, 86], the differential effect that
increasing doses of a drug might have on the risk of
developing MC has not been evaluated until very recently.
A study based on a large database of longitudinal records
of clinical information [87] stratified patients in regard to
the dose of drugs prescribed, following defined daily doses
according to World Health Organization criteria. Differ-
ences in the risk of developing MC (expressed as odds
ratios) were not demonstrated between patients who
received\0.75, 0.75–1.25, and[1.25 defined daily doses
of NSAIDs, PPIs, SSRIs, or statins.
5 Limitations and Bias of Studies
on the Association Between Drugs and MC
It is certainly possible that exposure to certain drugs might
induce changes in susceptible individuals, leading them to
trigger or enhance inflammatory changes in the colonic
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been linked with MC induction, are, at the same time, well
recognized as causing drug-induced diarrhea. These
include gold salts, acarbose, ticlopidine, sertraline, and,
less frequently, PPIs and NSAIDs [31, 94] (Table 4).
However, if we consider the widespread use of most of
the drugs that have been related to MC onset, which rep-
resent some of the most consumed remedies in medicine, it
is highly unlikely that exposure to these drugs could con-
stitute a major independent cause for this disease. It is also
important to note that most MC patients lack a suggestive
prior drug history, which rules out drugs and/or their
metabolites as major etiological agents for this disease.
Furthermore, only a small number of the reported associ-
ations between drugs and MC have been based on a certain
probabilistic basis, based on World Health Organization
proposed criteria [36] or on the French method for the
assessment of causality in drug reactions [35].
Together with the limitations of establishing causal rela-
tionships, the criteria used to define ‘exposure to drugs’ varied
widely among different studies, ranging from the patient
receiving at least one prescription in the previous year
(without evidence about compliance) [92, 95], to in the pre-
vious 6 months [34]; current consumption (thus considered if
drug exposure occurred within 3 months of the onset of
symptoms) [86]; recent exposure (between 2 and 3 months
prior to the date a MC diagnosis was established) [87]; and to
continuous or frequent intake at least 3 days per week for 2
weeks or more [34–52]. The average exposure time to a given
suspected drug beforeMC-compatible symptomonset has not
been uniformly considered amongst the different studies.
Thus, the study of imputability of Beaugerie and Pardi [39]
displayed a wide range of times between drug exposure and
the development of watery diarrhea, ranging from 1 day to 3
months, although the trend was towards a rapid onset of
Table 4 Frequency of drugs causing diarrhea (taken from Abraham et al. 2012 [32], reproduced with permission from Elsevier)
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symptoms at a median of 4 days. A recent study that analyzed
the effect of drug exposure timing on the risk of developing
MC in patients receiving PPIs and NSAIDs showed a signif-
icantly increased risk among patients with current and/or
recent exposure, compared with those with previous use of
both drugs [87].
Finally, the case–control studies that have shown sta-
tistically significant associations between certain drugs and
MC did so by considering different types of reference
populations, from the general population [81, 83, 86, 87],
to patients with irritable bowel syndrome [51, 70], func-
tional watery diarrhea [34], or patients undergoing surgery
[52].
6 Diagnosis of MC in Drug-Exposed Patients:
How to Proceed in Clinical Practice
Despite mounting evidence involving different drugs in the
origin or the aggravation of MC, we cannot exclude
completely that the association between the two entities
represents no more than a chance finding, especially when
the drugs less frequently involved are considered. Thus,
taking into account that the population most likely to be
diagnosed with MC is also the most exposed to drugs,
defining how to proceed in clinical practice when a patient
receiving ‘risky’ drugs is diagnosed with MC represents an
especially relevant topic. In this regard, currently available
recommendations are based on expert opinion because
specific studies demonstrating the superiority of one strat-
egy over the other are still lacking.
Owing to the fact that the drugs currently being taken by
a patient and those recently introduced have been more
closely related to the risk of developing MC [81, 87], a
detailed review of the drug history for possible causative
agents is essential in all patients with chronic watery
diarrhea and a MC diagnosis. It is also advisable not to start
a specific treatment for MC (budesonide, for example) until
a pharmacological origin has been ruled out.
The initial measure should consist, therefore, in with-
drawing the suspected drug (if unnecessary, dispensable, or
of dubious efficacy); if the patient cannot do without it, the
drug should be replaced by another of similar efficacy. The
clinical response should be evaluated after 10–14 days, and
if the patient reports a clinical improvement, the thera-
peutic strategy should consist in avoiding the suspected
drug, and additional corticosteroid-based treatment.
Unfortunately, the publications having reported on the
effect of such drug withdrawal on clinical manifestations of
MC are still very limited [71, 96]. In the event that with-
drawing or replacing the drug is not justified for medical
reasons, it is advisable to start a specific budesonide-based
treatment as in patients with non-drug-induced MC.
7 Conclusions
Diarrhea is a common side effect of multiple drugs
appearing via a range of causes. Several studies, mainly
retrospective case-control studies, have associated MC
with exposure to some commonly used drugs. However,
this result cannot unequivocally be the cause–effect rela-
tionship in all cases, but rather provides new research
avenues around the associations described. A certain
cause–effect relationship between drug exposure and MC
has only been described in a handful of drugs and in
individual cases.
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